367 related articles for article (PubMed ID: 35838210)
1. Therapeutic Potential of P2X7 Purinergic Receptor Modulation in the Main Organs Affected by the COVID-19 Cytokine Storm.
Batista Simões JL; Sobierai LD; Pereira SM; Rodrigues Dos Santos MV; Bagatini MD
Curr Pharm Des; 2022; 28(22):1798-1814. PubMed ID: 35838210
[TBL] [Abstract][Full Text] [Related]
2. Targeting purinergic receptors to suppress the cytokine storm induced by SARS-CoV-2 infection in pulmonary tissue.
Leão Batista Simões J; Fornari Basso H; Cristine Kosvoski G; Gavioli J; Marafon F; Elias Assmann C; Barbosa Carvalho F; Dulce Bagatini M
Int Immunopharmacol; 2021 Nov; 100():108150. PubMed ID: 34537482
[TBL] [Abstract][Full Text] [Related]
3. Anti-inflammatory Therapy by Cholinergic and Purinergic Modulation in Multiple Sclerosis Associated with SARS-CoV-2 Infection.
Simões JLB; de Araújo JB; Bagatini MD
Mol Neurobiol; 2021 Oct; 58(10):5090-5111. PubMed ID: 34247339
[TBL] [Abstract][Full Text] [Related]
4. Inflammation Triggered by SARS-CoV-2 and ACE2 Augment Drives Multiple Organ Failure of Severe COVID-19: Molecular Mechanisms and Implications.
Iwasaki M; Saito J; Zhao H; Sakamoto A; Hirota K; Ma D
Inflammation; 2021 Feb; 44(1):13-34. PubMed ID: 33029758
[TBL] [Abstract][Full Text] [Related]
5. Impact of cytokine storm and systemic inflammation on liver impairment patients infected by SARS-CoV-2: Prospective therapeutic challenges.
Ali FEM; Mohammedsaleh ZM; Ali MM; Ghogar OM
World J Gastroenterol; 2021 Apr; 27(15):1531-1552. PubMed ID: 33958841
[TBL] [Abstract][Full Text] [Related]
6. Cross-Talk Between Key Players in Patients with COVID-19 and Ischemic Stroke: A Review on Neurobiological Insight of the Pandemic.
Kaushik P; Kaushik M; Parveen S; Tabassum H; Parvez S
Mol Neurobiol; 2020 Dec; 57(12):4921-4928. PubMed ID: 32813238
[TBL] [Abstract][Full Text] [Related]
7. A novel definition and treatment of hyperinflammation in COVID-19 based on purinergic signalling.
Hasan D; Shono A; van Kalken CK; van der Spek PJ; Krenning EP; Kotani T
Purinergic Signal; 2022 Mar; 18(1):13-59. PubMed ID: 34757513
[TBL] [Abstract][Full Text] [Related]
8. Immunological Aspects of SARS-CoV-2 Infection and the Putative Beneficial Role of Vitamin-D.
Peng MY; Liu WC; Zheng JQ; Lu CL; Hou YC; Zheng CM; Song JY; Lu KC; Chao YC
Int J Mol Sci; 2021 May; 22(10):. PubMed ID: 34065735
[TBL] [Abstract][Full Text] [Related]
9. Do inflammaging and coagul-aging play a role as conditions contributing to the co-occurrence of the severe hyper-inflammatory state and deadly coagulopathy during COVID-19 in older people?
Xu K; Wei Y; Giunta S; Zhou M; Xia S
Exp Gerontol; 2021 Aug; 151():111423. PubMed ID: 34048906
[TBL] [Abstract][Full Text] [Related]
10. Coronavirus-19 (SARS-CoV-2) induces acute severe lung inflammation via IL-1 causing cytokine storm in COVID-19: a promising inhibitory strategy.
Conti P; Caraffa A; Gallenga CE; Ross R; Kritas SK; Frydas I; Younes A; Ronconi G
J Biol Regul Homeost Agents; 2020; 34(6):1971-1975. PubMed ID: 33016027
[TBL] [Abstract][Full Text] [Related]
11. Soluble P2X7 Receptor Is Elevated in the Plasma of COVID-19 Patients and Correlates With Disease Severity.
García-Villalba J; Hurtado-Navarro L; Peñín-Franch A; Molina-López C; Martínez-Alarcón L; Angosto-Bazarra D; Baroja-Mazo A; Pelegrin P
Front Immunol; 2022; 13():894470. PubMed ID: 35663992
[TBL] [Abstract][Full Text] [Related]
12. Purinergic receptor ligands: the cytokine storm attenuators, potential therapeutic agents for the treatment of COVID-19.
Zarei M; Sahebi Vaighan N; Ziai SA
Immunopharmacol Immunotoxicol; 2021 Dec; 43(6):633-643. PubMed ID: 34647511
[TBL] [Abstract][Full Text] [Related]
13. Putative mechanism of neurological damage in COVID-19 infection.
Bandala C; Cortes-Altamirano JL; Reyes-Long S; Lara-Padilla E; Ilizaliturri-Flores I; Alfaro-Rodríguez A
Acta Neurobiol Exp (Wars); 2021; 81(1):69-79. PubMed ID: 33949163
[TBL] [Abstract][Full Text] [Related]
14. Anti-SARS-CoV-2 and anti-cytokine storm neutralizing antibody therapies against COVID-19: Update, challenges, and perspectives.
Batista CM; Foti L
Int Immunopharmacol; 2021 Oct; 99():108036. PubMed ID: 34371330
[TBL] [Abstract][Full Text] [Related]
15. Molecular pathways triggered by COVID-19 in different organs: ACE2 receptor-expressing cells under attack? A review.
Saba L; Gerosa C; Fanni D; Marongiu F; La Nasa G; Caocci G; Barcellona D; Balestrieri A; Coghe F; Orru G; Coni P; Piras M; Ledda F; Suri JS; Ronchi A; D'Andrea F; Cau R; Castagnola M; Faa G
Eur Rev Med Pharmacol Sci; 2020 Dec; 24(23):12609-12622. PubMed ID: 33336781
[TBL] [Abstract][Full Text] [Related]
16. Cyclosporine A Inhibits Viral Infection and Release as Well as Cytokine Production in Lung Cells by Three SARS-CoV-2 Variants.
Fenizia C; Galbiati S; Vanetti C; Vago R; Clerici M; Tacchetti C; Daniele T
Microbiol Spectr; 2022 Feb; 10(1):e0150421. PubMed ID: 34985303
[TBL] [Abstract][Full Text] [Related]
17. Mast cells activated by SARS-CoV-2 release histamine which increases IL-1 levels causing cytokine storm and inflammatory reaction in COVID-19.
Conti P; Caraffa A; Tetè G; Gallenga CE; Ross R; Kritas SK; Frydas I; Younes A; Di Emidio P; Ronconi G
J Biol Regul Homeost Agents; 2020 Sep-Oct,; 34(5):1629-1632. PubMed ID: 32945158
[TBL] [Abstract][Full Text] [Related]
18. Modulation of IRAK enzymes as a therapeutic strategy against SARS-CoV-2 induced cytokine storm.
Mahmoud IS; Jarrar YB; Febrimarsa
Clin Exp Med; 2023 Oct; 23(6):2909-2923. PubMed ID: 37061574
[TBL] [Abstract][Full Text] [Related]
19. Tocilizumab in SARS-CoV-2 Patients with the Syndrome of Cytokine Storm: A Narrative Review.
Kulanthaivel S; Kaliberdenko VB; Balasundaram K; Shterenshis MV; Scarpellini E; Abenavoli L
Rev Recent Clin Trials; 2021; 16(2):138-145. PubMed ID: 32940187
[TBL] [Abstract][Full Text] [Related]
20. COVID-19: from the structure and replication cycle of SARS-CoV-2 to its disease symptoms and treatment.
Zawilska JB; Lagodzinski A; Berezinska M
J Physiol Pharmacol; 2021 Aug; 72(4):. PubMed ID: 34987123
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
